Ideaya Biosciences announced that the FDA has granted Fast Track designation to Ideaya’s development program investigating IDE161, a potent and selective inhibitor of poly glycohydrolase, for the treatment of adult patients having advanced or metastatic hormone receptor positive, or HR+, Her2- breast cancer with germline or somatic BRCA 1/2 mutations who have progressed following treatment with at least one line of a hormonal therapy, a CDK4/6 inhibitor therapy and a poly polymerase inhibitor therapy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on IDYA:
- Ideaya Biosciences granted Fast Track designation for IDE161 program by FDA
- Ideaya Biosciences initiates monotherapy expansion in IDE161 trial
- Biotech Alert: Searches spiking for these stocks today
- Ideaya Biosciences announces FDA clearance of GSK101 IND application
- Ideaya Biosciences doses first patient in darovasertib trial